Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 167

Results For "development"

2929 News Found

Parexel appoints Peyton Howell and Amy McKee
People | September 16, 2022

Parexel appoints Peyton Howell and Amy McKee

These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers


Everstone acquires controlling stake in Softgel Healthcare
News | September 16, 2022

Everstone acquires controlling stake in Softgel Healthcare

Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.


Zydus receives final approval from USFDA for Lenalidomide Capsules
Drug Approval | September 15, 2022

Zydus receives final approval from USFDA for Lenalidomide Capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India


Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics
People | September 15, 2022

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics

He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets


ProBioGen receives Employer of the Future and the Top Service awards
News | September 14, 2022

ProBioGen receives Employer of the Future and the Top Service awards

They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.


Lonza appoints Daniel Palmacci as President of the Cell & Gene Division
People | September 13, 2022

Lonza appoints Daniel Palmacci as President of the Cell & Gene Division

He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Diagnostic Center | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Diagnostic Center | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Diagnostic Center | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


WuXi STA opens a new sterile lipid nanoparticle formulation facility
News | September 11, 2022

WuXi STA opens a new sterile lipid nanoparticle formulation facility

This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform